The estimated Net Worth of Ryan Edward Brown is at least $8.75 Milion dollars as of 21 June 2024. Mr Brown owns over 38,957 units of Sarepta Therapeutics Inc stock worth over $2,199,192 and over the last 4 years he sold SRPT stock worth over $6,546,521.
Mr has made over 2 trades of the Sarepta Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 38,957 units of SRPT stock worth $6,295,841 on 21 June 2024.
The largest trade he's ever made was selling 38,957 units of Sarepta Therapeutics Inc stock on 21 June 2024 worth over $6,295,841. On average, Mr trades about 3,151 units every 9 days since 2021. As of 21 June 2024 he still owns at least 17,129 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Mr Brown stock trades at the bottom of the page.
Ryan E. Brown is the Sr. VP, Gen. Counsel & Corp. Sec. at Sarepta Therapeutics Inc.
Mr Brown is 43, he's been the Sr. VP a Gen. Counsel & Corp. Sec. of Sarepta Therapeutics Inc since . There are 16 older and no younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry a M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include: